Intellia Therapeuticsは、5月12日に開催されたBank of Americaグローバル・ヘルスケア・カンファレンスにおいて、遺伝性血管性浮腫（HAE）を対象とした第III相HALO試験の速報データを発表しました。その結果、本疾患の患者に対して実質的な臨床的ベネフィットがあることが示されました。
同社の最高財務責任者（CFO）であるEdward Dulac氏は、セッションの中で今回の調査結果を「非常に勇気づけられるもの」と説明しました。すべての患者が有意義な臨床的改善を達成し、28週間の主要観察期間終了時点で62％の患者が発作を起こさず、かつ治療を必要としませんでした。発作発生率の低下は80％台後半に達しており、Dulac氏は、この成果は同分野におけるこれまでの報告と同等か、あるいはそれを上回るものであると述べています。
AIによるレポート AIによって生成された画像 事実確認済み
A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.
HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.
AIによるレポート
Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.
A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.
AIによるレポート
An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.
A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.